These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27657659)

  • 1. Viral evasion and challenges of hepatitis C virus vaccine development.
    Pierce BG; Keck ZY; Foung SK
    Curr Opin Virol; 2016 Oct; 20():55-63. PubMed ID: 27657659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C vaccine. Need of the hour.
    Verma R; Khanna P; Chawla S
    Hum Vaccin Immunother; 2014; 10(7):1927-9. PubMed ID: 25424801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design.
    Kong L; Jackson KN; Wilson IA; Law M
    Curr Opin Virol; 2015 Apr; 11():148-57. PubMed ID: 25932568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges for development of hepatitis C virus vaccines.
    Prince AM
    FEMS Microbiol Rev; 1994 Jul; 14(3):273-7. PubMed ID: 8086198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus vaccines--progress and perspectives.
    Fauvelle C; Lepiller Q; Felmlee DJ; Fofana I; Habersetzer F; Stoll-Keller F; Baumert TF; Fafi-Kremer S
    Microb Pathog; 2013 May; 58():66-72. PubMed ID: 23499591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies.
    Wasilewski LN; El-Diwany R; Munshaw S; Snider AE; Brady JK; Osburn WO; Ray SC; Bailey JR
    J Virol; 2016 Jan; 90(7):3773-82. PubMed ID: 26819308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome: an accelerated approach toward epitope-driven vaccine development.
    Abdel-Hady KM; Gutierrez AH; Terry F; Desrosiers J; De Groot AS; Azzazy HM
    Hum Vaccin Immunother; 2014; 10(8):2366-77. PubMed ID: 25424944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transmitted/Founder Viruses Rapidly Escape from CD8+ T Cell Responses in Acute Hepatitis C Virus Infection.
    Bull RA; Leung P; Gaudieri S; Deshpande P; Cameron B; Walker M; Chopra A; Lloyd AR; Luciani F
    J Virol; 2015 May; 89(10):5478-90. PubMed ID: 25740982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of linear B-cell epitopes of hepatitis C virus for vaccine development.
    Huang WL; Tsai MJ; Hsu KT; Wang JR; Chen YH; Ho SY
    BMC Med Genomics; 2015; 8 Suppl 4(Suppl 4):S3. PubMed ID: 26680271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Multiantigenic DNA Vaccine That Induces Broad Hepatitis C Virus-Specific T-Cell Responses in Mice.
    Gummow J; Li Y; Yu W; Garrod T; Wijesundara D; Brennan AJ; Mullick R; Voskoboinik I; Grubor-Bauk B; Gowans EJ
    J Virol; 2015 Aug; 89(15):7991-8002. PubMed ID: 26018154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity.
    Yusim K; Fischer W; Yoon H; Thurmond J; Fenimore PW; Lauer G; Korber B; Kuiken C
    J Gen Virol; 2010 May; 91(Pt 5):1194-206. PubMed ID: 20053820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus--T-cell responses and viral escape mutations.
    Petrovic D; Dempsey E; Doherty DG; Kelleher D; Long A
    Eur J Immunol; 2012 Jan; 42(1):17-26. PubMed ID: 22125159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing.
    Baumert TF; Fauvelle C; Chen DY; Lauer GM
    J Hepatol; 2014 Nov; 61(1 Suppl):S34-44. PubMed ID: 25443345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects for prophylactic hepatitis C vaccines based on virus-like particles.
    Beaumont E; Roingeard P
    Hum Vaccin Immunother; 2013 May; 9(5):1112-8. PubMed ID: 23406827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies.
    Lauer GM
    J Infect Dis; 2013 Mar; 207 Suppl 1():S7-S12. PubMed ID: 23390305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immune evasion mechanisms of hepatitis C virus. Review].
    Porto-Espinoza L; Cuadra-Sánchez C; Moronta R; Monsalve-Castillo F; Callejas-Valero D
    Invest Clin; 2006 Mar; 47(1):71-82. PubMed ID: 16562646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogen-Associated Molecular Pattern Recognition of Hepatitis C Virus Transmitted/Founder Variants by RIG-I Is Dependent on U-Core Length.
    Kell A; Stoddard M; Li H; Marcotrigiano J; Shaw GM; Gale M
    J Virol; 2015 Nov; 89(21):11056-68. PubMed ID: 26311867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8+ T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses.
    Zhang S; Bakshi RK; Suneetha PV; Fytili P; Antunes DA; Vieira GF; Jacobs R; Klade CS; Manns MP; Kraft AR; Wedemeyer H; Schlaphoff V; Cornberg M
    J Virol; 2015 Aug; 89(16):8304-17. PubMed ID: 26041301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in developing a cross-serotype rhinovirus vaccine.
    Glanville N; Johnston SL
    Curr Opin Virol; 2015 Apr; 11():83-8. PubMed ID: 25829255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine.
    Latimer B; Toporovski R; Yan J; Pankhong P; Morrow MP; Khan AS; Sardesai NY; Welles SL; Jacobson JM; Weiner DB; Kutzler MA
    Hum Vaccin Immunother; 2014; 10(8):2357-65. PubMed ID: 25424943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.